MedTrace Logo

A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355

NCT03802162 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-10-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of CKD-355.

Conditions

  • Alzheimer's Disease (AD)

Interventions

DRUG

CKD-355A (D797/Memantine HCl 20mg)

once a day

DRUG

CKD-355B (D797/Memantine HCl 20mg)

once a day

DRUG

D797

once a day

DRUG

D324 (Memantine HCl 10mg)

twice a day

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2019-05-10
Completion
2019-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03802162 on ClinicalTrials.gov